Trial Profile
Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Allopurinol; Antithymocyte globulin; Bendamustine; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia; Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms RV-CLL-PI-0294
- 14 Jan 2020 Status changed from completed to discontinued.
- 13 Mar 2019 Status changed from active, no longer recruiting to completed.
- 30 May 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2019.